Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) study

American Heart Journal

Volumn 154, Issue 2, 2007, Pages 345-351

  Hassan, Walid ^a   Al Sergani, Hani ^a   Al Buraiki, Jehad ^a   Dunn, Bruce ^a   Al Turki, Fawaz ^a   Akhras, Nathem ^a   ElShaer, Fayez ^a   Nawaz, Mahboob ^a   Kharabsheh, Suliman ^a   ElKum, Naser ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE;

ADULT; AGED; ARTICLE; BLEEDING; BOLUS INJECTION; CONTINUOUS INFUSION; CORONARY STENT; DIABETES MELLITUS; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FEMALE; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; STENTS; TIME FACTORS;

EID: 34447552489     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.04.020     Document Type: Article

References (30)

1. Mizuno k., Satomura K., Miyamoto A., et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 326 (1992) 287-291
2. White C.J., Ramee S.R., Collins T.J., et al. Coronary thrombi increase PTCA risk: angioscopy as a clinical tool. Circulation 93 (1996) 253-258
3. Fuster V., Badimon L., Badimon J., et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326 (1992) 242-250
4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: the EPIC Investigation. N Engl J Med 330 (1994) 956-961
5. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 (1997) 1689-1696
6. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349 (1997) 1429-1435
7. The IMPACT-II Investigators. Randomized placebo-controlled trial of the effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimize Platelet Aggregation and Coronary Thrombosis-II. Lancet 349 (1997) 1422-1428
8. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: randomized efficacy study of tirofiban for outcomes and restenosis. Circulation 96 (1997) 1445-1453
9. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 352 (1998) 87-92
10. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 356 (2000) 2037-2044
11. Kong D.F., Califf R.M., Miller D.P., et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 98 (1998) 2829-2835
12. Anderson K.M., Califf R.M., Stone G.W., et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 37 (2001) 2059-2065
13. Karvouni E., Katritsis D.G., and Ioannidis J.P. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 41 (2003) 26-32
14. Cohen D.J., Lincoff A.M., Lavelle T.A., et al. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 44 (2004) 1792-1800
15. Mitchel J.F., and Alberghini T.V. Site-specific thrombolysis with Reopro. Circulation 94 (1996) 1202
16. Mitchel J.F., and Alberghini T.V. Local delivery of Reopro: pharmacokinetics and effect on platelet deposition following balloon angioplasty. Circulation 94 (1996) 1202
17. Baily S.R., O'Leary E., and Chilton R. Angioscopic evaluation of site-specific administration of Reopro. Catheter Cardiovasc Diagn 42 (1997) 181-184
18. Bartorelli A.L., Trabattoni D., Galli S., et al. Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA. Catheter Cardiovasc Interv 48 (1999) 211-213
19. Hassan W., Nambiar V., Al-Habeeb W., et al. Rescue in situ thrombolysis for acute coronary thromboembolism in an angiographically normal coronary artery. Saudi Med J 25 (2004) 2007-2009
20. Wohrle J., Grebe O.C., Nusser T., et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 107 (2003) 1840-1843
21. Kakkar A.K., Moustapha A., Hanley H.G., et al. Comparison of intracoronary vs intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv 61 (2004) 31-34
22. O'Shea J.C., Hafley G., Greenberg S., et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: a randomized controlled trial. JAMA 285 (2001) 2468-2473
23. O'Shea J.C., Buller C., Canton W., et al. Long term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 287 (2001) 618-621
24. Hassan W.M., Flaker G.C., Feutz C., et al. Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: a randomized trial. J Thromb Thrombolysis 2 (1995) 245-249
25. Rao A.K., Pratt C., Berke A., et al. Thrombolysis in Myocardial Infarction (TIMI) trial: phase 1, hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11 (1988) 1-11
26. Lincoff A.M., Califf R.M., Moliterno D.J., et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors: evaluation of platelet IIb/IIIa inhibition in stenting investigators. N Engl J Med 341 (1999) 319-327
27. Lincoff A.M., Califf R.M., and Topol E.J. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 35 (2000) 1103-1115
28. Tcheng J.E., Strony J., Lorenz T.J., et al. ESPRIT in context: pharmacology matters!. Eur Heart J 22 (2001) 1965-1967
29. Pinto D.S., Kirtane A.J., Ruocco N.A., et al. Administration of intracoronary eptifibatide during ST-elevation myocardial infarction. Am J Cardiol 95 (2005) 1494-1497
30. Deibele A.J., Kirtane A.J., Pinto D.S., et al. Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Thrombolysis 22 (2006) 47-50